The safety and efficacy of EGF-based cream for the prevention of radiotherapy-induced skin injury: results from a multicenter observational study

• 발행기관: 대한방사선종양학회
• 저자명: Hyun-Cheol Kang MD Seung-Do Ahn MD PhD Doo-Ho Choi MD PhD Min Kyu Kang MD Woong-Ki Chung MD PhD Hong-Gyun Wu MD PhD
• 간행물 정보: 『대한방사선종양학회지』제32권 제3호, 156~162쪽, 전체 7쪽
• 주제분류: 의약학 > 종양학
• 파일형태: PDF
• 발행일자: 2014.09.30

영문 초록

Purpose: This study was designed to evaluate the efficacy and safety of topically applied recombinant human epidermal growth factor (rhEGF) for the prevention of radiation-induced dermatitis in cancer patients. Materials and Methods: From December 2010 to April 2012, a total of 1,172 cancer patients who received radiotherapy (RT) of more than 50 Gy were prospectively enrolled and treated with EGF-based cream. An acute skin reaction classified according to the Radiation Therapy Oncology Group 6-point rating scale was the primary end point and we also assessed the occurrence of edema, dry skin, or pruritus. Results: The percentage of radiation dermatitis with maximum grade 0 and grade 1 was 19% and 58% at the time of 50 Gy, and it became 29% and 47% after completion of planned RT. This increment was observed only in breast cancer patients (from 18%/62% to 32%/49%). Adverse events related to the EGF-based cream developed in 49 patients (4%) with mild erythema the most common. Skin toxicity grade >2 was observed in 5% of the patients. Edema, dry skin, and pruritus grade ≥3 developed in 9%, 9%, and 1% of the patients, respectively. Conclusion: Prophylactic use of an EGF-based cream is effective in preventing radiation dermatitis with tolerable toxicity. Further studies comparing EGF cream with other topical agents may be necessary.

목차

1. Introduction

2. Materials and Methods

3. Results

4. Discussion and Conclusion

5. Conflict of Interest

6. Acknowledgments

7. References

키워드

Radiation induced dermatitis Cancer Radiotherapy Dermatitis Epidermal growth factor